Trials no longer actively enrolling patients:
- Bespoke IO 20-043-NCP (Natera) – A BESPOKE Study of ctDNA Guided Immunotherapy for Non-Small cell lung cancer, Melanoma, and Colorectal cancer. (NCT Number: NCT04761783)
- CORFU (AstraZeneca) – Retrospective/Observational Study of Risk of Adverse Events in NSCLC Patients Treated with Immune Checkpoint Inhibitors Followed by EGFR Tyrosine Kinase Inhibitors
- I3Y-MC-JPCW(b) (Eli Lilly)– A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib plus Standard Adjuvant Endocrine Therapy in Participants with High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy (NCT number: NCT04752332)
- Prevalence (Janssen Research & Development) – Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer. Observational study (NCT number: NCT03871816)